Lymphopenia As a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

Overview

Journal Cancer Res

Specialty Oncology

Date 2009 Jun 25

PMID 19549917

Citations 384

Authors

Isabelle Ray-Coquard

Claire Cropet

Martine Van Glabbeke

Catherine Sebban

Axel Le Cesne

Ian Judson

Olivier Tredan

Jaap Verweij

Pierre Biron

Inthidar Labidi

Jean-Paul Guastalla

Thomas Bachelot

David Perol

Sylvie Chabaud

Pancras C W Hogendoorn

Philippe Cassier

Armelle Dufresne

Jean-Yves Blay

Affiliations

Soon will be listed here.

Abstract

Lymphopenia is frequent in advanced cancers and predicts the toxicity of chemotherapy. Its effect on relapse and survival is uncertain. Its prognostic value for survival was analyzed in three databases of previously reported prospective multicenter studies: (a) FEC chemotherapy in metastatic breast carcinoma; (b) CYVADIC in advanced soft tissue sarcoma (European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group 62791); and (c) prospective, consecutive phase III studies of aggressive diffuse large-cell non-Hodgkin's lymphomas conducted at Centre Léon Bérard between 1987 and 1993. Univariate and multivariate analyses of prognostic factors for survival were performed. The incidence of lymphopenia of <1,000/microL before treatment was constant among the series: 25%, 24%, and 27%, respectively. Lymphopenia was significantly more frequent (P < 0.05) in metastatic breast cancer patients with performance status (PS) of >1, non-Hodgkin's lymphoma patients with international prognostic index (IPI) of > 0, and advanced soft tissue sarcoma and metastatic breast cancer patients with bone metastases. Inunivariate analysis, lymphopenia of <1,000/microL significantly correlated to overall survival in patients with metastatic breast cancer (median, 10 versus 14 mo; P < 0.0001), advanced soft tissue sarcoma (median, 5 versus 10 months; P < 0.01), and non-Hodgkin lymphoma (median, 11 versus 94 months; P < 0.0001). In multivariate analysis (Cox model), lymphopenia was an independent prognostic factor for overall survival in metastatic breast cancer [RR (relative risk), 1.8; 95% CI (confidence interval), 1.3-2.4] along with liver metastases and PS; in advanced soft tissue sarcoma (RR, 1.46; 95% CI, 1.0-2.1) along with liver metastases, lung metastases, and PS; and in non-Hodgkin's lymphoma (RR, 1.48; 95% CI, 1.03-2.1) along with IPI. Our findings show that lymphopenia is an independent prognostic factor for overall and progression-free survival in several cancers.

Citing Articles

Prognostic roles nutritional index in patients with resectable and advanced biliary tract cancers.

Zeng D, Wen N, Wang Y, Cheng N, Li B World J Gastroenterol. 2025; 31(6):97697.

PMID: 39958446 PMC: 11752707. DOI: 10.3748/wjg.v31.i6.97697.

Systemic inflammation index is a predictive and prognostic factor in patients with liposarcoma or leiomyosarcoma treated with trabectedin.

Sobczuk P, Filipowicz P, Lamparski L, Kosela-Paterczyk H, Teterycz P, Kozak K Sci Rep. 2025; 15(1):5247.

PMID: 39939795 PMC: 11821830. DOI: 10.1038/s41598-025-89977-z.

Correlations among lymphocyte count, white matter hyperintensity and brain atrophy in patients with ischemic stroke.

Liu C, Shi D, Ni X, You S, Wu X, Zhuang S Front Aging Neurosci. 2025; 16():1492078.

PMID: 39845446 PMC: 11751001. DOI: 10.3389/fnagi.2024.1492078.

Enabling immune checkpoint blockade efficacy in T-lymphopenia by restoring CD8 T cell dynamics with IL-7 cytokine therapy.

Kang Y, Choi D, Moon D, Lee K, Oh Y, Yang J Front Immunol. 2025; 15:1477171.

PMID: 39763661 PMC: 11701376. DOI: 10.3389/fimmu.2024.1477171.

Preoperative prediction of lymph node metastasis in intrahepatic cholangiocarcinoma: an integrative approach combining ultrasound-based radiomics and inflammation-related markers.

Peng Y, Pang J, Lin P, Chen J, Wen R, Liu C BMC Med Imaging. 2025; 25(1):4.

PMID: 39748308 PMC: 11697736. DOI: 10.1186/s12880-024-01542-8.

References

Hennessy B, Hanrahan E, Daly P . Non-Hodgkin lymphoma: an update. Lancet Oncol. 2004; 5(6):341-53. DOI: 10.1016/S1470-2045(04)01490-1. View

Dyer A . A method for combining results from several prospective epidemiologic studies. Stat Med. 1986; 5(4):303-17. DOI: 10.1002/sim.4780050403. View

Ayoub J, Palmer J, Huh Y, Cabanillas F, Younes A . Therapeutic and prognostic implications of peripheral blood lymphopenia in patients with Hodgkin's disease. Leuk Lymphoma. 1999; 34(5-6):519-27. DOI: 10.3109/10428199909058479. View

Alexandre J, Rey E, Girre V, Grabar S, Tran A, Montheil V . Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Ann Oncol. 2006; 18(1):168-172. DOI: 10.1093/annonc/mdl321. View

RIESCO A . Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer. 1970; 25(1):135-40. DOI: 10.1002/1097-0142(197001)25:1<135::aid-cncr2820250120>3.0.co;2-9. View

Dahm P, Gail M, Rosenberg P, Pee D . Determining the value of additional surrogate exposure data for improving the estimate of an odds ratio. Stat Med. 1995; 14(23):2581-98. DOI: 10.1002/sim.4780142307. View

Hasenclever D, Diehl V . A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998; 339(21):1506-14. DOI: 10.1056/NEJM199811193392104. View

Mazur G, Bogunia-Kubik K, Wrobel T, Kuliczkowski K, Lange A . TGF-beta1 gene polymorphisms influence the course of the disease in non-Hodgkin's lymphoma patients. Cytokine. 2006; 33(3):145-9. DOI: 10.1016/j.cyto.2005.12.010. View

Blay J, Farcet J, Lavaud A, Radoux D, Chouaib S . Serum concentrations of cytokines in patients with Hodgkin's disease. Eur J Cancer. 1994; 30A(3):321-4. DOI: 10.1016/0959-8049(94)90249-6. View

10.

Casasnovas R, Mounier N, Brice P, Divine M, Morschhauser F, Gabarre J . Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007; 25(13):1732-40. DOI: 10.1200/JCO.2006.08.1331. View

11.

Hoffmann T, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson J . Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002; 8(8):2553-62. View

12.

Chauvin F, Magnet M, Lasset C, Catimel G, Mayer M, Chevarier P . [Prognostic factors in the response of a first line chemotherapy in advanced breast cancer]. Bull Cancer. 1990; 77(9):941-7. View

13.

Seymour J, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R . Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol. 1995; 13(3):575-82. DOI: 10.1200/JCO.1995.13.3.575. View

14.

Voorzanger N, Touitou R, Garcia E, Delecluse H, Rousset F, Joab I . Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res. 1996; 56(23):5499-505. View

15.

Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A . Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie. J Clin Oncol. 2004; 22(12):2371-8. DOI: 10.1200/JCO.2004.06.121. View

16.

Zhang H, Chua K, Guimond M, Kapoor V, Brown M, Fleisher T . Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med. 2005; 11(11):1238-43. DOI: 10.1038/nm1312. View

17.

Thomachot M, Bendriss-Vermare N, Massacrier C, Biota C, Treilleux I, Goddard S . Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1a(high)CD86(-)Langerin- and CD1a(+)CD86(+)Langerin+ phenotypes. Int J Cancer. 2004; 110(5):710-20. DOI: 10.1002/ijc.20146. View

18.

Kim H, Hong M, Dan J, Kang I . Altered IL-7Ralpha expression with aging and the potential implications of IL-7 therapy on CD8+ T-cell immune responses. Blood. 2005; 107(7):2855-62. PMC: 1440715. DOI: 10.1182/blood-2005-09-3560. View

19.

Choi C, Sung H, Park K, Yoon S, Kim S, Oh S . Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. Am J Hematol. 2003; 73(4):263-6. DOI: 10.1002/ajh.10363. View

20.

Goldrath A, Bevan M . Selecting and maintaining a diverse T-cell repertoire. Nature. 1999; 402(6759):255-62. DOI: 10.1038/46218. View